Introduction {#Sec1}
============

Monocytes, macrophages, and microglia are mononuclear phagocytes important in innate immunity and also key reservoirs of human immunodeficiency virus-1 (HIV-1) in the central nervous system (CNS). These reservoirs present a challenge to HIV eradication as they continue to produce virus in tissue despite antiretroviral therapy. Our group recently showed that cystatin B, a cysteine protease inhibitor, is upregulated in blood monocyte-derived macrophages (MDM) compared to placental macrophages, which are less susceptible than MDM to HIV-1 infection (Luciano-Montalvo et al. [@CR16]). Intracellular expression of cystatin B was increased in HIV-1-infected MDM at 12 days post-infection (Luciano-Montalvo et al. [@CR16]) and in the secretome of HIV-1-infected MDM (Ciborowski et al. [@CR5]; Garcia-Crespo et al. [@CR8]), suggesting that this protein is activated during HIV infection. A direct connection between cystatin B and HIV replication was demonstrated using small interfering RNA against cystatin B (Luciano-Montalvo et al. [@CR16]). Subsequently, the signaling mechanisms for cystatin B in HIV replication were related to its interaction with signal transducer and activator of transcription-1 (STAT-1) (Luciano-Montalvo and Melendez [@CR15]). Whereas STAT-1 activates HIV-1 replication, high levels of tyrosine phosphorylated STAT-1 (STAT-1PY) have been associated with HIV-1 inhibitory activity (Chang et al. [@CR2]). Interestingly, recent data from our laboratory using more specific monoclonal antibodies showed higher levels of STAT-1PY in placental macrophages, a cell that restricts HIV replication, than in MDM (Luciano-Montalvo and Melendez [@CR15]), and very low levels in MDM until 12 days after infection. Low levels of cystatin B together with high levels of STAT-1PY may restrict HIV replication in placental macrophages, whereas high levels of cystatin B and low levels of STAT-1PY may promote HIV replication in MDM (Luciano-Montalvo and Melendez [@CR15]). However, the signaling pathways and mechanisms for increased HIV-1 replication in MDM are yet to be determined.

Although cystatin B is recognized primarily as a cysteine protease inhibitor rather than a regulatory protein, Di Giamo et al. identified five recombinant proteins that interact with cystatin B, none of which is a protease (Di Giamo et al. [@CR6]). Those investigators suggested a role of the cystatin B multiprotein complex in the cerebellum; disruption of which correlated with the etiology and pathogenesis of progressive myoclonus epilepsy, a degenerative disease of the central nervous system. That was the first time cystatin B was reported to be part of a multiprotein complex with an unknown function. In the present study, we identified proteins interacting with cystatin B in order to elucidate the relationship between this protein, STAT-1 phosphorylation, and HIV-1 replication in MDM.

Type I interferons α and β (IFN-α and IFN-β) are antiviral proteins important in innate immunity. The production of IFN-β is a rapid and very effective antiviral response to HIV in cultured macrophages (Gessani et al. [@CR9], [@CR10]). In the present study, we found that cystatin B inhibited the IFN-β response in Vero cells by preventing STAT-1 translocation to the nucleus and decreasing levels of STAT-1PY. The discovery of this mechanism of cystatin B regulation of STAT-1 phosphorylation could inform the development of new therapeutic approaches that aim to inhibit the long terminal repeat (LTR)-mediated HIV replication by modulating the site of STAT-1 phosphorylation in favor of tyrosine instead inhibiting STAT-1 expression.

Results {#Sec2}
=======

Proteins associated with cystatin B {#d28e363}
-----------------------------------

To determine whether cystatin B interacts with other key players regulating STAT-1 phosphorylation and HIV-1 replication, cystatin B was immunoprecipitated from HIV-1-infected MDM as described previously (Luciano-Montalvo and Melendez [@CR15]), and the protein complex was analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). We found that cystatin B interacts with many different proteins in HIV-1-infected cells, including regulatory, glycolytic, metabolic, structural, transport, proteases, and immune proteins (Table [1](#Tab1){ref-type="table"}). Most of the proteins identified (25 of 37) associated with cystatin B in HIV-1-infected cells but not in uninfected controls. Two proteins did not associate with cystatin B in HIV-infected cells, but did so in uninfected controls: cathepsin B (a cysteine protease inhibited by cystatin B) and elongation factor 1. Bound proteins were not detected in the negative control, pre-cleared MDM lysates incubated with unconjugated beads.Table 1Cystatin B-associated proteins from HIV-1-infected MDM and uninfected controls**Protein name**AccessionMolecular\# peptideUniProtWeight (Da)ControlHIV +**Regulatory proteins** Major vault proteinQ1476499,326.3314 Lymphocyte-specific protein 1P3324137,191.302**Glycolytic enzymes** Pyruvate kinase M1/M2P1461857,936.646 Human alpha-enolaseP0673347,168.706 Glyceraldehyde-3 phosphate dehydrogenaseP0440636,053.005 [l]{.smallcaps}-lactate dehydrogenase AP0033836,688.502 Fructose-1,6-bisphosphatase 1P0946736,814.204**Metabolic proteins** Peroxisomal multifunctional enzyme type 2P5165979,685.902 Sulfide: quinoneoxidoreductasemitochondrialQ9Y6N549,960.405 TransketolaseP2940165,33302 Heat shock protein HSP90 alphaP0790084,659.102 V-type proton ATPase subunit B, brain isoformP2128156,500.402 ATP synthase subunit alpha, mitochondrialP2570559,750.303 Synaptic vesicle membrane protein VAT-1 homologQ9953641,92003**Structural proteins** Elongation factor 1P6810450,140.520 Annexin A2P0735538,603.848 Myosin 9 (MYH9)P35579226,529.8536 Actin Cytoplasmic 1/2P6326141,736.559 VimentinP0867053,651.329 Macrophage-capping proteinP4012138,517.325 Cofilin-1P2352818,502.402 Plastin-2P1379670,288.9411 Myosin regulatory light chainP0597621,14504 MoesinP2603867,819.504 Protein disulfideisomeraseA6Q1508448,12162 Human Filamin-AP21333280,735.406 GelsolinP0639685,696.903 Ras GTPase- activating-like proteinP46940189,25208 Alpha-actinin-1P12814103,056.902 Protein S100-A11P3194911,740.402**Transport-related proteins** Clathrin heavy chain 1Q00610191,612.663 ADP-ribosylation factor 1/3Q9NZ5220,696.602 Transferrin receptor protein 1Q5RDH684,87102**Proteases** Cathepsin BP0785837,82220 Cathepsin DP0733944,55202**Immune protein** HLA class I histocompatibility antigenP3048845,00002

Validation of immunoprecipitated proteins {#d28e1042}
-----------------------------------------

Major vault protein (MVP), and pyruvate kinase M2 (PKM2) were selected for validation by Western blot after co-immunoprecipitation with cystatin B antibody because these proteins are known to be involved in the regulation of STAT-1 phosphorylation and HIV-1 replication. Western blot studies confirmed that cystatin B interacted with PKM2 isoform, a protein previously associated with cocaine enhancement of HIV-1 replication, and MVP, an IFN-responsive protein that interferes with IFN-activated JAK/STAT signals (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Validation of immunoprecipitated proteins by Western blot. MVP, and PKM2 were selected to be validated by Western blot after co-immunoprecipitation with cystatin B antibody because they are involved in the regulation of STAT-1 phosphorylation and HIV-1 replication. *CSTB* cystatin B; *U87* U87 whole cell lysates used as positive controls; *C-* controls for non-specific binding using unconjugated beads and MDM lysates; *HIV-1 +* MDM lysates inoculated with HIV-1~ADA~, *HIV-1* uninfected MDM lysates

Studies of HIV-infected and uninfected MDM using immunofluorescence and confocal imaging demonstrated overexpression of MVP in HIV-infected cells (Fig. [2](#Fig2){ref-type="fig"}). These results extend those of Steiner et al. ([@CR23]), who previously reported MVP--STAT coexpression in tumor cells induced by IFN-γ. To our knowledge, the current study is the first to demonstrate the coexpression of STAT-1 and MVP in HIV-1-infected MDM.Fig. 2Overexpression of MVP in HIV-1-infected MDM at 12 days post-infection. Immunofluorescence and confocal imaging confirmed that MVP-STAT coexpression is increased in HIV-1-infected MDM. *Control* uninfected MDM; *HIV-1 +* HIV-1-infected MDM at 12 days post-infection. *Green fluorescence* represents MVP and *red fluorescence* represents STAT-1

Cystatin B inhibition of IFN-β response in Vero cells {#d28e1107}
-----------------------------------------------------

To test if cystatin B inhibits the IFN-β response, we performed luciferase reporter gene assays in Vero cells, which are IFN deficient. Robust IFN stimulation of gene 54 (ISG54)-driven expression of firefly luciferase was seen in cells transfected with an empty vector, and this stimulation was abolished in cells transfected with a cystatin B vector (Fig. [3](#Fig3){ref-type="fig"}). Furthermore, the interferon response of IFN-β-treated Vero cells expressing cystatin B was significantly inhibited as compared with the results before IFN treatment.Fig. 3Cystatin B inhibition of IFN-β response in Vero cells. Interferon stimulation of gene 54 (*ISG54*)-driven expression of firefly luciferase was significantly inhibited in cells transfected with a cystatin B vector compared to cells transfected with the empty vector. **a** Plasmid construct containing the ISG54 promoter fused to firefly luciferase and the SV40 promoter fused to Renilla luciferase. **b** Vector used to induce expression of cystatin B. **c** Luciferase reporter gene assays in Vero cells. Cells were transiently transfected with an empty vector (mock) or a vector expressing cystatin B (*Cst B*) and stimulated with 500 U/mL IFN (*IFN+*) or left untreated (*IFN−*). Twenty-four hours posttreatment, the cells were lysed and the luciferase activity was measured by using a dual luciferase assay (Promega). Firefly luciferase units were divided by Renilla units to obtain relative luciferase units (RLU). Mean of four independent experiments, \**p* \< 0.05. *Error bars* represent ±SEM

Inhibition of STAT-1 nuclear translocation and tyrosine phosphorylation in response to cystatin B {#d28e1152}
-------------------------------------------------------------------------------------------------

We used immunofluorescence and confocal imaging on Vero cells transiently transfected with a vector expressing cystatin B to determine if this protein alters nuclear translocation of STAT-1. Vero cells transfected with an empty vector or a vector expressing NIPAH-V were used as negative and positive controls, respectively. NIPAH-V was used because it is known to inhibit the IFN-β response via inhibition of STAT-1 translocation to the nucleus (Rodriguez et al. [@CR21]). Before IFN-β treatment, all STAT-1 immunoreactivity was localized to the cytosol. STAT-1 immunoreactivity was translocated to the nucleus after IFN-β treatment in the negative empty control, but retained in the cytoplasm of the NIPAH-V control, and in Vero cells expressing cystatin B (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Inhibition of nuclear translocation of STAT-1 by cystatin B expression. Immunofluorescence and confocal imaging of Vero Cells transiently transfected with a vector expressing cystatin B shows that cystatin B alters the nuclear translocation of STAT-1 after treatment with 500 U/mL IFN-β. Vero cells transfected with an empty vector (control) or a vector expressing NIPAH-V were used as negative and positive controls, respectively. Blue fluorescent DAPI nucleic acid stain was used as nuclear stain

The effect of cystatin B on the expression of STAT-1PY was determined by Western blots (Fig. [5](#Fig5){ref-type="fig"}). Vero cells were transfected with cystatin B plasmid for a period of 24 h. Overexpression of cystatin B was demonstrated in transfected cells with cystatin B vector after normalization with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (\**p* \< 0.05) (Fig. [5a](#Fig5){ref-type="fig"}, b). Cystatin B inhibited STAT-PY in Vero cells (\**p* \< 0.05) (Fig. [5a](#Fig5){ref-type="fig"}, c). When IFN was added to cultures in presence of cystatin B, there was a reduction in STAT-PY relative to cystatin B-untreated cells that approached significance (*p* = 0.06) (Fig. [5a](#Fig5){ref-type="fig"}, c). These results demonstrated that cystatin B inhibits the IFN-β response and the nuclear translocation of STAT-1 and a tendency to decreases the expression of STAT-1PY in Vero cells.Fig. 5Decreased levels of STAT-1PY expression are associated with cystatin B expression. The effect of cystatin B on the expression of STAT-1PY was determined by Western blots. Vero cells were either mock transfected or transfected with cystatin B plasmid for a period of 24 h. IFN-β (500 U/ml) was added to the cultures. Whole cell lysates were collected after 24 h of IFN exposure. The expression of STAT-1PY and cystatin B is shown in presence and absence of IFN (**a**). Overexpression of cystatin B is demonstrated in cells transfected with cystatin B vector after normalization with GAPDH (\**p* \< 0.05) (**b**). Cells transfected with cystatin B demonstrated a decreased ratio of STAT-1PY over cystatin B and a tendency to decrease in the presence of IFN-β (*p* = 0.09) (**c**). *Control lanes* represent cultures that were not transfected with a vector. This experiment is representative of three biological replicates

Discussion {#Sec3}
==========

HIV-1-associated neurocognitive disorders result from HIV-1 infection of the brain, alterations in the blood--brain barrier, migration of activated monocytes, and a subsequent induced immune activation response. HIV-1 replication and neurotoxicity are both related to the type of STAT-1 phosphorylation. STAT-1 serine phosphorylation (STAT-1PS) promotes blood--brain barrier damage (Chaudhuri et al. [@CR3]), whereas STAT-1PY has been associated with HIV-1 inhibitory activity (Chang et al. [@CR2]). Cystatin B has been associated with decreased levels of STAT-1PY and increased HIV-1 replication in MDM (Luciano-Montalvo and Melendez [@CR15]). However, the pathways and the mechanisms by which cystatin B interacts with STAT-1 are unknown. Recently, cystatin B has also been shown to interact with cathepsin B in HIV-negative macrophages but fails to interact in HIV-negative MDM (Rodriguez et al. [@CR21]). More recently, our group found that cystatin B also fails in protecting against HIV-1 neuropathogenesis by lack of inhibition of the cysteine protease cathepsin B, a potent neurotoxin. In this study, we provide evidence that cystatin B interacts with many different proteins in HIV-1-infected MDM, indicating that cystatin B performs other functions in addition to inhibiting cysteine protease. Furthermore, our results demonstrated that cystatin B inhibits the IFN-β response and inhibits the nuclear translocation of STAT-1 and demonstrated a tendency to decreases the expression of STAT-1PY in Vero cells.

Our findings support the hypothesis that cystatin B interacts with proteins related to HIV-1 replication. Five enzymes associated with the glycolytic pathway, including the PKM2 isoform, were identified as cystatin B-associated proteins. PKM2 has been reported to be upregulated in association with cocaine enhancement of HIV-1 replication in normal human astrocytes (Reynolds et al. [@CR19]). In contrast, PKM2 is downregulated in HIV-1/vesicular stomatitis virus-infected murine microglia (Wang et al. [@CR24]). This downregulation of PKM2 occurs in parallel with the low levels of cystatin B associated with HIV-1 restriction in microglia (manuscript in revision). Cystatin B also seems to interact with proteins involved in the regulation of STAT-1 phosphorylation. One of these proteins is MVP, the main component of vaults. Vaults are large ribonucleoprotein particles implicated in the regulation of cellular signaling cascades and may act as scaffolds for proteins involved in signal transduction. The vaults are composed of three proteins: MVP, the telomerase-associated protein and the vault poly (ADP-ribose) polymerase. MVP has multiple roles in signal pathway regulation and immunity (Berger et al. [@CR1]) and is associated with PTEN and PI3K (Yu et al. [@CR27]), ERK and EGFR/SHP2/MAPK/Src (Kolli et al. [@CR14]), multidrug resistance (Kitazono et al. [@CR12], [@CR13]), and proteins associated with the ubiquitin pathway as COP1 (Yi et al. [@CR26]). In addition to all these functions, MVP is an IFN-γ-responsive gene that interferes with the IFN-γ-induced antiviral response mediated by STAT-1 signaling (Steiner et al. [@CR23]). Using tandem mass spectrometry, we found that MVP is also associated with cystatin B. In the present study, STAT-1 was not detected among the proteins associated with cystatin B by mass spectrometry. However, the co-immunoprecipitation of cystatin B and STAT-1 in HIV-infected MDM was previously demonstrated by our group using direct Western blot detection of STAT-1 in the cystatin B-immunoprecipitated pool of proteins (Luciano-Montalvo and Melendez [@CR15]). A possible explanation for the absence of STAT-1 in the IP LC-MS/MS analysis could be poor ionization of these peptides, masking by other ionized peptides, or data that did not pass our conservative exclusion criteria. The LC-MS/MS data are conservatively analyzed to accept as positive identifications only those data that pass these exclusion criteria: BioWorks® unified score of \>3,000, Xcorr for doubly charged precursor ion of \>2.5, DeltaCn of \>0.3, more than 60% of fragment ions per sequenced peptide, and at least two peptides per protein for identification.

Interestingly, the other cystatin B-associated protein related to HIV-1 replication, PKM2, is co-regulated at the gene and protein level by STAT-1 (Pitroda et al. [@CR18]) and is a phosphotyrosine-binding protein that binds directly and selectively to tyrosine-phosphorylated peptides (Christofk et al. [@CR4]). In the present study, the MVP and PKM2 proteins were chosen for verification by Western blot because they have been reported in the literature as being involved in HIV-1 replication and the regulation of STAT-1 phosphorylation. The presence of both protein bands was confirmed in Western blots of HIV-infected MDM. Furthermore, immunofluoresence and confocal imaging demonstrated increased the expression of MVP that colocalized with STAT-1 in HIV-1-infected MDM, as was reported earlier for tumor cells (Steiner et al. [@CR23]). To our knowledge, this is the first study to demonstrate the coexpression of cystatin B and MVP with HIV-1 replication in MDM. This finding points to these proteins as potential novel targets for anti-HIV therapy in macrophages, the principal reservoirs for HIV-1 in the CNS. Future studies will elucidate the exact role that cystatin B interactions with MVP and PKM2 play in STAT-1 phosphorylation and HIV replication in MDM.

Both neurotoxicity and HIV replication are related to the type of STAT-1 phosphorylation. STAT-1PS is detrimental in that it promotes blood--brain barrier damage (Chaudhuri et al. [@CR3]), whereas STAT-1PY is beneficial as it has been associated with HIV-1 inhibitory activity mediated by CD8 T lymphocyte antiviral factor (CAF) (Chang et al. [@CR2]). CAF inhibits LTR-mediated HIV replication by inducing the expression of interferon regulatory factor 1 (IRF-1), which is STAT-1PY dependent. STAT-1 inhibition has been suggested as a new therapeutic approach to clear HIV-1 macrophage reservoirs (Magnani et al. [@CR17]). Taking these data together, we propose that preventing viral replication in macrophages might be accomplished by modulating the site of STAT-1 phosphorylation in favor of tyrosine, as it is known that STAT-1PY inhibits LTR-mediated HIV replication. We also postulate that cystatin B may inhibit the signaling pathway mediated by IFN-β by regulating STAT-1 tyrosine phosphorylation. This action would prevent the expression of IFN-dependent antiviral genes and promote HIV replication mediated by LTR and IRF-1. To test if cystatin B inhibits the IFN-β response, we performed luciferase reporter gene assays in Vero cells, which are IFN deficient. ISG54-driven expression of firefly luciferase was significantly inhibited in Vero cells expressing cystatin B relative to cells transfected with the empty vector (Fig. [3](#Fig3){ref-type="fig"}). These findings allow us to propose two mechanisms for the high levels of HIV replication in MDM mediated by cystatin B: (1) a decrease in IFN-β-induced antiviral gene expression mediated by the STAT-1/IRF-1 complex and (2) an induction of HIV replication mediated by the NF-Kβ/IRF-1 complex.

Following cellular activation, the binding of cellular transcription factors such as NF-kβ to response elements in the HIV-1 promoter results in marked upregulation of HIV replication (Kinoshita et al. [@CR11]). NF-kβ transcriptional activity requires the IRF-1 to induce HIV replication by formation of a complex at the HIV-1 LTR. The NF-kβ/IRF-1 complex binds to the gene promoter and induces HIV replication (Sgarbanti et al. [@CR22]). Furthermore, NF-kβ suppresses both antiviral and immunomodulatory actions of IFN-β against influenza virus (Wei et al. [@CR25]), whereas in NF-kβ knockout mice, IFN-β induced the binding of STAT-1 and IRF-1 to activate genes (Wei et al. [@CR25]). STAT-1PY has been associated with HIV-1 inhibitory activity (Chang et al. [@CR2]) and recent studies by our group showed that cystatin B is associated with a reduction in STAT-1PY and HIV replication in MDM (Luciano-Montalvo and Melendez [@CR15]), and together these findings provide support for a role of cystatin B in HIV replication. On the basis of our results and a review of relevant literature, we propose a mechanism to explain how cystatin B promotes viral replication in macrophage reservoirs (Fig. [6](#Fig6){ref-type="fig"}). We propose that the reduction of STAT-1PY prevents the formation of the STAT-1PY/IRF-1 complex, thus inhibiting the expression of antiviral genes induced by IFN-β. The induction of IRF-1 expression by IFN-β (Fujita et al. [@CR7]) and its availability due to low levels of STAT-1PY allows the formation of the NFk-β/IRF-1 complex that induces LTR-mediated HIV replication. Future studies will be aimed at elucidating the role of cystatin B in regulating the JAK/STAT-1 pathway and LTR-mediated HIV-1 replication in MDM and determining whether cystatin B is a novel regulatory protein and if MVP plays a role in this interaction. These studies may prove important for the development of inhibitory therapeutic directed against macrophage HIV reservoirs.Fig. 6Proposed mechanism for cystatin B stimulation of viral replication in macrophage reservoirs. Cystatin B may regulate STAT-1 phosphorylation and thus control LTR-mediated replication and interferon-induced antiviral response, resulting in increased HIV replication in macrophage reservoirs. The *numbers* indicate the approach to be used to assess each step: (*1*) immunoprecipitation followed by LC-MS/MS, (*2*) immunoprecipitation followed by Western blot, (*3*) luciferase assay of IFN-treated and untreated Vero cells, (*4*) as reported in the literature: *4a* (Fujita et al. [@CR7]); *4b* (Sgarbanti et al. [@CR22]); *4c* (Steiner et al. [@CR23])

Materials and methods {#Sec4}
=====================

Monocyte isolation, cultivation, and HIV-1 infection {#d28e1372}
----------------------------------------------------

Peripheral blood mononuclear cells were isolated from the peripheral blood of healthy donors after appropriate consents were obtained in accordance with the University of Puerto Rico Medical Sciences Campus Institutional Review Board protocol \#0720109. The cells were seeded into T-25 flasks as adherent MDM cultures in RPMI media supplemented with 10% human serum, 20% fetal bovine serum, 100 U/mL pen/strep, and 2 mM glutamine. On day 7, MDMs were exposed to HIV-1~ADA~ stock using a multiplicity of infection of 0.1 by overnight incubation or left untreated as negative controls. One day after exposure to the virus, a full media exchange was performed; thereafter, a half media exchange was done every 2 days. Supernatants at 6, 9, and 12 days post-infection were collected to monitor infection by HIV-1 p24 antigen ELISA (Express BioTech International, Thurmont, MD) following the manufacturer's instructions. MDMs were maintained for 12 days in culture and lysed on ice with lysis buffer \[5 mM Tris--HCl buffer, pH 8, 0.1% Triton X-100, and protease inhibitor cocktail (Sigma, St. Louis, MO)\].

Immunoprecipitation {#d28e1380}
-------------------

Monoclonal antibodies against cystatin B (Sigma, St. Louis, MO) were used for protein-specific immunoprecipitation from cell lysates using an Exacta homologous IP/WB kit (Santa Cruz Biotechnology, Santa Cruz, CA) as described previously (Luciano-Montalvo and Melendez [@CR15]). Whole cell lysates were pre-cleared by immunoprecipitation with beads for 1 h, and the samples were incubated with antibody-conjugated beads overnight followed by several washes. The pre-cleared lysates were incubated with unconjugated beads as controls for non-specific binding. The U87 whole cell lysates were used as a positive control for cystatin B.

LC-MS/MS {#d28e1388}
--------

Immunoprecipitated proteins were digested in solution by an overnight incubation with trypsin (0.1 μg/μl) at 37°C. Peptides were extracted \[60% acetonitrile with 0.1% trifluoroacetic acid (TFA)\], dried, and then resuspended (0.5% TFA) prior to purification using ZipTip® (Millipore Corporation, Billerica, MA). Peptides were resuspended in 2% acetonitrile with 0.1% formic acid prior to fractionation on a microcapillary RP-C~18~ column (New Objectives, Woburn, MA). The peptides were then fragmented and sequenced with a nanospray ionization configuration using a LTQ XL MS/MS (ThermoElectron, Thermo Fisher Scientific, Walthan, MA). The spectra obtained were searched against UniProtKB/Swiss-prot.fasta indexed for human proteins using the Turbo SEQUEST search engine (BioWorks 3.2). Protein hits were subjected to exclusion criteria and accepted as positive with high confidence if two or more unique peptides were sequenced per protein. Immunoprecipitation and protein identification experiments were performed with two different cultures from different donors.

Western blot analyses {#d28e1396}
---------------------

The MDM-immunoprecipitated proteins and Vero cell lysates were diluted with Laemmli sample buffer (BioRad, Hercules, CA) applied to a 10% Tris--HCl Ready Gel (BioRad, Hercules, CA) and transferred to 0.45-μm nitrocellulose membranes (BioRad, Hercules, CA). After blocking with 5% bovine serum albumin in Tris-buffered saline, membranes were incubated with mouse anti-cystatin B (1:500, Sigma, St. Louis, MO). MDM-immunoprecipitated proteins were immunoblotted with mouse anti PKM2 (1:500, Abcam, Cambridge, MA) and rabbit anti-MVP (1:100, Abcam, Cambridge, MA). For immunoprecipitated proteins, the U87 and HeLa cell lysates were used as positive control for cystatin B. The Vero cells were immunoblotted with mouse anti-STAT-1PY (1:500 Abcam, Cambridge, MA). Empty vector was used as mock-transfected control and untransfected cells as negative controls. Mouse GAPDH (1:1,000) (Abcam) was used as the loading control. Signal was detected using the Super Signal® West Femto Maximum Sensitivity Substrate (Thermo). The density of protein bands was determined using the VersaDoc Imaging System (BioRad Laboratories, Hercules, CA) with Quantity One software and normalized against GAPDH.

Immunofluorescence and confocal imaging of MDM {#d28e1401}
----------------------------------------------

Monocyte isolation, cultivation, and HIV-1 infection were performed using the Lab-Tek Chamber Slides (Fisher, Pittsburgh, PA) in adherent cultures. The MDMs were fixed, permeabilized, and incubated overnight with anti-rabbit MVP (1:100, Abcam, Cambridge, MA) and anti-mouse STAT-1 (1:500, Abcam, Cambridge, MA) primary antibodies, and for 1 h with ALEXA-conjugated secondary antibody (Invitrogen, Carlsbad, CA). Confocal images were obtained on a Zeiss LSM 5 confocal laser-scanning microscope.

Co-transfection and luciferase reporter gene assays {#d28e1406}
---------------------------------------------------

Vero cells, which are IFN deficient, were grown in minimum essential medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum to reach 70--80% confluence. To induce the expression of cystatin B, 7.5 × 10^5^ cells were seeded in 6-well plates and incubated overnight. Three grams of *Homo sapiens* cystatin B as transfection-ready DNA NM_000100.2 inserted in pCMV6-XL5 (OriGene, Rockville, MD) or empty pcDNA3.1 vector was transfected with Lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, together with 1 g of a plasmid construct containing the ISG54 promoter fused to firefly luciferase and the SV40 promoter fused to Renilla luciferase (provided by Dr. Muñoz). The cells were stimulated with 500 U/mL of IFN-ß (PBL Interferon Source, Piscataway, NJ) in Opti-MEM I Reduced Serum Medium (Invitrogen, Carlsbad, CA) or left untreated. Twenty-four hours posttreatment, the cells were lysed and the luciferase activity was measured via a Triathler luminometer by using a dual luciferase assay (Promega) as recommended by the manufacturer. Firefly luciferase units were divided by Renilla units to obtain relative luciferase units.

Immunofluorescence and confocal imaging of Vero Cells {#d28e1417}
-----------------------------------------------------

Vero cells were grown, co-transfected, and stimulated with 500 U/mL of IFN-β as described before. The Vero cells were fixed, permeabilized, and incubated overnight with anti-rabbit STAT-1 (1:500, Abcam, Cambridge, MA) primary antibodies and for 1 h with ALEXA-conjugated secondary antibody (Invitrogen, Carlsbad, CA). Blue-fluorescent DAPI nucleic acid stain was used as the nuclear stain. Confocal images were obtained on a Zeiss confocal microscope Axiovert 200M with a LSM 510.
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